One Verdict, Many Lives: FDA’s Shift in Approval Philosophy

From the hush of regulatory offices to the bright lights of clinical labs, a subtle but consequential shift is underway. The institutional rhythm of drug development — long anchored on two independent clinical trials for each approval — is being reoriented. The echo of a second trial is fading; in its place, a single, well-designed study may soon suffice. For patients, researchers, and drug companies alike, this may mark the start of a new era — one promising speed and accessibility, but also raising questions about how we balance haste and safety.

The FDA, under the leadership of Commissioner Marty Makary, has announced that it will begin requiring just one clinical trial — rather than the historical standard of two — for many new drugs and medical products to be considered for approval. While the agency retains discretion to ask for more trials when warranted, this shift reflects a broader regulatory philosophy that a single, robust trial may provide sufficient evidence of efficacy and safety.

The rationale, according to the FDA, is rooted in pragmatism. Modern trial design techniques, statistical methods, and accumulated experience mean that sometimes a single well-powered, rigorous “pivotal” trial may deliver clearer answers than two smaller or overlapping trials. For certain conditions — especially those lacking effective therapies — this could translate into faster access for patients in real need.

Simultaneously, the FDA is easing requirements for approval of biosimilar and biologic products, reducing the need for multiple human comparative-efficacy studies when analytical and other non-clinical data demonstrate similarity to reference products.

Still, critics — including some independent researchers — warn this may come at a cost. Historically, requiring two trials helped guard against chance findings, design flaws, or statistical flukes; with just one trial, the risk that a drug’s benefits or risks are not fully understood at approval grows. There is also concern that reduced public disclosure about supporting evidence could erode transparency, making it harder for doctors, patients, and watchdogs to evaluate truly how well a medication works beyond initial results.

For patients eagerly awaiting new treatments — especially for rare diseases, serious chronic illnesses, or conditions with little to no current therapy — the change could bring relief and hope. For regulators, drugmakers, and the medical community, it opens a door to faster innovation. But for many experts, the shift also underscores the enduring tension between urgency and caution in medicine.

How this balancing act plays out in the years ahead may shape not just the pace of new therapies — but the trust we place in them, the standards we accept, and ultimately, the health outcomes for those who rely on them.

AI Image Disclaimer Visuals are produced using AI tools and meant solely as conceptual illustrations — not real photographs.

Sources STAT News; U.S. Food and Drug Administration; Oregon State University research; ACS’ C&EN; FDA / HHS press release